Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week, Multi-Centre, Open-Label, Single-Arm, Phase IV Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) With Daily Dose 600mg-750mg as Mono-Therapy in the Treatment of Acute Schizophrenic Patients

NCT00428350 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00428350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00428350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week, Multi-Centre, Open-Label, Single-Arm, Phase IV Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) With Daily Dose 600mg-750mg as Mono-Therapy in the Treatment of Acute Schizophrenic Patients
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2006
Completion date
September 30, 2007
Enrollment
120 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia